ジカウイルス治療薬の市場規模・シェア・成長分析 (ワクチンの種類別、検査の種類別、エンドユーザー別、地域別)：産業予測 (2025～2032年)

世界のジカウイルス治療薬の市場規模は、2023年に20億米ドルと評価され、予測期間（2025～2032年）のCAGRは13.6%で、2024年の22億7,000万米ドルから2032年には63億米ドルに成長する見通しです。

世界のジカウイルス治療薬市場は、感染率の上昇、進行中の医薬品研究開発、予防とワクチン接種をめぐる意識の高まりにより大きな成長を遂げています。主に蚊によって媒介されるジカ熱は、特に熱帯地域において深刻な出生異常や神経学的問題を引き起こし、需要をさらに促進しています。mRNA技術やデジタルモニタリングツールなどの技術の進歩は、ワクチンの開発と安全性を加速させています。例えば、Modernaの革新的なmRNA-1893ワクチンは現在臨床試験中で、生きた株を利用せずに効率的にウイルスと闘うことを目指しています。さらに、AI、機械学習、ブロックチェーン技術の統合は、ワクチンの生産と流通の効率を高めています。これらのイノベーションは、信頼を築き、効果的な治療を促進し、一般市民を啓蒙することで、ジカ熱治療薬の需要を再構築しています。

目次

イントロダクション

• 分析目的
• 市場範囲
• 定義

分析手法

• 情報調達
• 二次・一次データの手法
• 市場規模予測
• 市場の想定と制約

エグゼクティブサマリー

• 市場の概要と展望
• 需給動向の分析
• セグメント別の機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

市場の主な考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場魅力度指数 (2024年)
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

世界のジカウイルス治療薬の市場規模・CAGR：ワクチンの種類別 (2025～2032年)

• 市場概要
• 不活化ウイルスワクチン
• 生弱毒化ワクチン
• DNAワクチン
• mRNAワクチン

世界のジカウイルス治療薬の市場規模・CAGR：検査の種類別 (2025～2032年)

• 市場概要
• 分子検査
• 血清学的検査

世界のジカウイルス治療薬の市場規模・CAGR：エンドユーザー別 (2025～2032年)

• 市場概要
• 病院と診療所
• 調査機関

世界のジカウイルス治療薬の市場規模・CAGR：流通チャネル別 (2025～2032年)

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

世界のジカウイルス治療薬の市場規模・CAGR (2025～2032年)

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング (2024年)
• 主要企業が採用した戦略
• 市場の近年の動向
• 主要企業の市場シェア (2024年)
• 主要企業のプロファイル
  • 企業概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較 (2022～2024年)

主要企業プロファイル

• Moderna Inc.（USA）
• Valneva SE（France）
• Inovio Pharmaceuticals, Inc.（USA）
• Emergent BioSolutions Inc.（USA）
• Novavax, Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Bharat Biotech International Ltd.（India）
• GeoVax Labs, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（GSK）（UK）
• BioCryst Pharmaceuticals, Inc.（USA）
• Zydus Cadila（India）
• GeneOne Life Science Inc.（South Korea）
• Kimer Med（Spain）
• BioVaxys Technology Corporation（Canada）
• Creative Diagnostics（USA）
• Indian Immunologicals Limited（India）
• Sanofi Pasteur（France）

結論と提言

Global Zika Virus Therapeutics Market size was valued at USD 2.0 billion in 2023 and is poised to grow from USD 2.27 billion in 2024 to USD 6.3 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

The global Zika virus therapeutics market is witnessing significant growth due to rising infection rates, ongoing pharmaceutical research and development, and heightened awareness surrounding prevention and vaccination. Primarily transmitted by mosquitoes, Zika causes severe birth defects and neurological issues, particularly in tropical regions, further driving demand. Technological advancements, such as mRNA technology and digital monitoring tools, have accelerated the development and safety of vaccines. For example, Moderna's innovative mRNA-1893 vaccine is currently in clinical trials, aiming to efficiently combat the virus without utilizing live strains. Additionally, the integration of AI, machine learning, and blockchain technology is enhancing vaccine production and distribution efficiency. These innovations are building trust, promoting effective treatments, and educating the public, reshaping demand in the Zika therapeutics landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Zika Virus Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Zika Virus Therapeutics Market Segments Analysis

Global Zika Virus Therapeutics Market is segmented by Vaccine Type, Test Type, End User, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Virus Vaccine, Live Attenuated Vaccine, DNA Vaccine and mRNA Vaccine. Based on Test Type, the market is segmented into Molecular Test and Serological Test. Based on End User, the market is segmented into Hospitals and Clinics and Research Institutes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Zika Virus Therapeutics Market

The rising incidence of Zika virus, especially in tropical and subtropical areas, is driving the growth of the global Zika virus therapeutics market. Factors such as increased global travel, climate change, urbanization, and the expanding mosquito population are intensifying the need for effective prevention and treatment measures. In response to this growing threat, governments and international health organizations are making substantial investments in Zika virus prevention strategies, further boosting the demand for therapeutics. This surge in investment and awareness is critical in addressing the escalating challenges posed by the Zika virus on public health.

Restraints in the Global Zika Virus Therapeutics Market

The global Zika virus therapeutics market faces significant restraints primarily due to the high costs associated with the development process. These expenses arise from the intricate nature of research and development, along with the necessity for multiple clinical trials prior to vaccine introduction. Additionally, varying acceptance criteria set by regulatory bodies such as the ICMRA in India, the FDA in the United States, and the European Union necessitate ongoing research and heavier investments. Furthermore, many vaccines demand cold storage and efficient cold chain logistics, which subsequently elevate operational costs, thereby posing additional challenges in bringing effective therapeutics to market.

Market Trends of the Global Zika Virus Therapeutics Market

The Global Zika Virus Therapeutics market is witnessing a significant trend towards the advancement of vaccine technologies, particularly with the emergence of mRNA and DNA platforms. These innovative technologies enable faster and more efficient vaccine development, allowing companies to respond swiftly to outbreaks. The accelerated approval process by regulatory bodies, coupled with the growing endorsement from medical organizations, fosters greater acceptance and confidence in these vaccines among the public. As global health agencies prioritize Zika virus prevention, the market is poised for robust growth, driven by enhanced research activities, collaborative efforts, and increased investment in novel therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Zika Virus Therapeutics Market Size by Vaccine Type & CAGR (2025-2032)

• Market Overview
• Inactivated Virus Vaccine
• Live Attenuated Vaccine
• DNA Vaccine
• mRNA Vaccine

Global Zika Virus Therapeutics Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Molecular Test
• Serological Test

Global Zika Virus Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Research Institutes

Global Zika Virus Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Zika Virus Therapeutics Market Size & CAGR (2025-2032)

• North America (Vaccine Type, Test Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Test Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Test Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Test Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Test Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Moderna Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kimer Med (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVaxys Technology Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations